MedTrace Logo

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

NCT07320326 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2026-01-06

No results posted yet for this study

Summary

This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.

Conditions

  • TCE-RRMM

Interventions

DRUG

Elranatamab

In the retrospective period, Each patient will be followed up until two years after the first dose of Elranatamab treatment, death, or withdrawal of consent, whichever occurs first. Information collection will be performed every month for the first 6 months after the first dose of Elranatamab treatment and then every 3 months for the following 18 months. The prospective period will include a Screening Period and a Treatment Period. Screening Period assessments will be performed within 7 days prior to treatment. During the Treatment Period, each patient will be followed up until two years after the first dose of Elranatamab treatment, death, or withdrawal of consent, whichever occurs first.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Peking University People's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-30
Primary Completion
2028-07-18
Completion
2028-09-18

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07320326 on ClinicalTrials.gov